A potent, competitive, and selective antagonist of P2X7 purinergic receptor (pIC50 = 6.5nM and 6.9nM for rat and human P2X7 receptor, respectively). Shown to reduce ATP-induced reactive oxygen species formation in MEL cells by about 87% (~10uM) and blocks BzATP-stimulated changes in intracellular calcium concentrations (IC50 = 100 and 300nM at rat and human P2X7 receptors, respectively. Developed by Abbott.
Synonyms:3-((5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methyl)pyridine Hydrochloride; P2X7 Purinergic Receptor Antagonist; A 438079; A438079; A-438079
Molecular Formula:C₁₃H₉Cl₂N₅•HCl
Molecular Weight:DMSO
Appearance:Supplied as an off-white solid
Purity:≥99% (HPLC)
Solubility (100mM):DMSO, 20mg/ml, clear
Carbon Content:44-46%
Hydrogen Content:2.30-3.70%
Nitrogen Content:19-21%
Water by CHN (mol):≤1mol
Primary Target:P2X7
Storage and Stability:May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
